Immunome Inc. (IMNM)
Immunome Statistics
Share Statistics
Immunome has 87.01M shares outstanding. The number of shares has increased by 44.99% in one year.
| Shares Outstanding | 87.01M |
| Shares Change (YoY) | 44.99% |
| Shares Change (QoQ) | 39.31% |
| Owned by Institutions (%) | 88.55% |
| Shares Floating | 75.47M |
| Failed to Deliver (FTD) Shares | 9.4K |
| FTD / Avg. Volume | 0.83% |
Short Selling Information
The latest short interest is 12.48M, so 14.36% of the outstanding shares have been sold short.
| Short Interest | 12.48M |
| Short % of Shares Out | 14.36% |
| Short % of Float | 14.92% |
| Short Ratio (days to cover) | 9.97 |
Valuation Ratios
The PE ratio is -2.13 and the forward PE ratio is -3.06. Immunome's PEG ratio is 0.3.
| PE Ratio | -2.13 |
| Forward PE | -3.06 |
| PS Ratio | 68.88 |
| Forward PS | 2.5 |
| PB Ratio | 3.44 |
| P/FCF Ratio | -5.28 |
| PEG Ratio | 0.3 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immunome.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.08 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $76.62K |
| Profits Per Employee | $-2.48M |
| Employee Count | 118 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -40.68% in the last 52 weeks. The beta is 2.06, so Immunome's price volatility has been higher than the market average.
| Beta | 2.06 |
| 52-Week Price Change | -40.68% |
| 50-Day Moving Average | 8.1 |
| 200-Day Moving Average | 11.48 |
| Relative Strength Index (RSI) | 63.73 |
| Average Volume (20 Days) | 1.13M |
Income Statement
In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.
| Revenue | 9.04M |
| Gross Profit | 6.94M |
| Operating Income | -305.8M |
| Net Income | -292.96M |
| EBITDA | -151.35M |
| EBIT | -153.46M |
| Earnings Per Share (EPS) | -5 |
Balance Sheet
The company has 143.35M in cash and 4.83M in debt, giving a net cash position of 138.52M.
| Cash & Cash Equivalents | 143.35M |
| Total Debt | 4.83M |
| Net Cash | 138.52M |
| Retained Earnings | -515.77M |
| Total Assets | 240.24M |
| Working Capital | 167.03M |
Cash Flow
In the last 12 months, operating cash flow was -110.79M and capital expenditures -7.17M, giving a free cash flow of -117.97M.
| Operating Cash Flow | -110.79M |
| Capital Expenditures | -7.17M |
| Free Cash Flow | -117.97M |
| FCF Per Share | -2.01 |
Margins
Gross margin is 76.75%, with operating and profit margins of -3382.37% and -3240.38%.
| Gross Margin | 76.75% |
| Operating Margin | -3382.37% |
| Pretax Margin | -3240.38% |
| Profit Margin | -3240.38% |
| EBITDA Margin | -1674.08% |
| EBIT Margin | -3382.37% |
| FCF Margin | -1304.8% |
Dividends & Yields
IMNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IMNM is $25, which is 181.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $25 |
| Price Target Difference | 181.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 3.3 |
| Piotroski F-Score | 2 |